Full Breakdown
Osteoporosis Medications Associated with Reduced Alzheimer’s Risk in Hong Kong Study
By Drooid · · How we work
Study Findings
A large observational study of 121,492 adults aged 60 or older in Hong Kong found that users of nitrogen-containing bisphosphonates (NBPs)—a class of drugs that slow bone loss—experienced a lower incidence of Alzheimer’s disease and related dementias compared with non-users.
Study Design and Population
All participants had been newly diagnosed with osteoporosis or had suffered a recent fragility fracture of the spine, humerus, wrist, or hip, and none had previously taken osteoporosis medication. The analysis compared three groups: (1) NBP users, (2) users of other osteoporosis drugs, and individuals not taking any osteoporosis medication. Baseline cognitive testing was unavailable, and information on fracture severity, over-the-counter calcium or vitamin D use, and external factors such as education level or social isolation was not collected.
Data & Statistics
- NBP users showed a 16 % lower risk of developing Alzheimer’s disease or related dementias relative to those not taking osteoporosis medication.
- Compared with users of other osteoporosis drugs, NBP users had a 24 % lower risk of the same outcomes.
These risk reductions are reported as associations observed in the cohort; the study design does not establish causation.
Expert Commentary
The study’s lead author, Ching-Lung Cheung, an associate professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong’s Li Ka Shing Faculty of Medicine, emphasized the preliminary nature of the findings:
- “Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial,” — Lung Cheung, study author
- “The next step is to confirm our observational findings in a clinical trial,” — Lung Cheung, study author
Cheung also noted emerging evidence of a “bone-brain axis,” suggesting that maintaining bone health may influence brain health, though he cautioned that the observational results require confirmation.
Implications and Next Steps
If future clinical trials verify a protective effect, NBPs could become part of broader dementia-risk-reduction strategies, especially for older adults with osteoporosis. The authors call for additional research that includes more diverse populations and examines potential gender differences in the observed association. Until such evidence is available, prescribing NBPs solely for dementia prevention is not supported.